Kairos Pharma, Ltd. will present positive safety and early efficacy data from its Phase 2 prostate cancer trial at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany, taking place 17–21 October.

The presentation, titled “Preliminary safety and clinical activity from a Phase 2 study of apalutamide and carotuximab in advanced, castration-resistant prostate cancer,” will highlight interim results from the randomized trial evaluating ENV105 (carotuximab), a first-in-class CD105 antagonist.

The study is enrolling 100 men with metastatic castration-resistant prostate cancer (mCRPC) at Cedars-Sinai Medical Center, City of Hope, and Huntsman Cancer Institute at the University of Utah. Participants are randomized to receive apalutamide with or without ENV105 after progression on prior hormone therapies.

Prostate cancer is one of the most diagnosed cancers in men, with over a million new cases in the US annually. Resistance to androgen-targeted therapies remains a significant clinical challenge for patients with mCRPC.

Neil Bhowmick, CSO of Kairos Pharma, said: “The data we will be presenting at the 2025 ESMO Congress demonstrates encouraging safety and early efficacy findings from our Phase 2 trial. This is an important venue for us to share the therapeutic potential of ENV105 for patients with few remaining treatment options after hormone therapy resistance develops.”

The interim analysis is intended to provide insights into ENV105’s potential as a treatment option in combination with apalutamide for patients who have limited alternatives after developing resistance to hormone therapies. The findings will be presented to an international oncology audience and may inform future study design and regulatory planning.